Skip to content

Study · Observational study · n = 543 · 2024

6 results

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).

Furusawa S, Nomoto H, Oba-Yamamoto C, Takeuchi J, Ito M, Kurihara H, Aoki S, Miya A, Kameda H, Nakamura A, Atsumi T

Endocrine journal25 Apr 2024Cited by 16 (Europe PMC)

PMID38658349 (opens in a new tab)DOI10.1507/endocrj.ej23-0648 (opens in a new tab)PepBankPUB-38658349
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studySafety outcome

    In adults with type 2 diabetes on oral semaglutide, 39 subjects (7.2%) discontinued semaglutide because of adverse events.

    In plain wordsIn adults with type 2 diabetes, 39 people (7.2%) stopped oral semaglutide because of side effects.

    Peptide
    Semaglutide
    Outcome
    Not applicableDiscontinuation due to adverse events
    Study

    n = 543

    Outcome group
    Adverse events · Whole body
    Studied dose
    3 mg, 7 mg or 14 mg · oral · 6 monthsAs given in this study (human).

    Measurements

    Discontinued due to adverse events
    39 subjects
    oral semaglutide

    Source sentences

    Summary
    39 (7.2%) were discontinued semaglutide due to the adverse events.
    2 context sentences
    Summary · context
    In this multi-center retrospective observational study, we analyzed subjects with type 2 diabetes newly treated with an oral semaglutide for >6 months at four medical centers located in Sapporo, Japan.
    Summary · context
    Of 543 subjects who met the inclusion criteria, data for 434 subjects (age 55.5 ± 12.6 years; body mass index 29.6 ± 6.0 kg/m2) were analyzed.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, glycated hemoglobin fell from 7.65% to 6.88% after about 6 months of oral semaglutide in routine care.

    In plain wordsIn adults with type 2 diabetes in routine care, blood sugar (glycated hemoglobin) improved over 6 months on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycated hemoglobin change
    Study

    n = 434

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 mg, 7 mg or 14 mg · oral · 6 monthsAs given in this study (human).

    Measurements

    HbA1c before
    7.65%
    baseline
    HbA1c after
    6.88%
    6 months

    Source sentences

    Summary
    Both glycated hemoglobin and body weight significantly improved: 7.65 ± 1.11% to 6.88 ± 0.91% (p < 0.001) and 80.2 ± 19.2 kg to 77.6 ± 19.2 kg (p < 0.001), respectively.
    2 context sentences
    Summary · context
    In this multi-center retrospective observational study, we analyzed subjects with type 2 diabetes newly treated with an oral semaglutide for >6 months at four medical centers located in Sapporo, Japan.
    Summary · context
    Of 543 subjects who met the inclusion criteria, data for 434 subjects (age 55.5 ± 12.6 years; body mass index 29.6 ± 6.0 kg/m2) were analyzed.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, body weight fell from 80.2 kg to 77.6 kg after about 6 months of oral semaglutide in routine care.

    In plain wordsIn adults with type 2 diabetes in routine care, body weight fell over 6 months on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 434

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg, 7 mg or 14 mg · oral · 6 monthsAs given in this study (human).

    Measurements

    Body weight before
    80.2 kg
    baseline
    Body weight after
    77.6 kg
    6 months

    Source sentences

    Summary
    Both glycated hemoglobin and body weight significantly improved: 7.65 ± 1.11% to 6.88 ± 0.91% (p < 0.001) and 80.2 ± 19.2 kg to 77.6 ± 19.2 kg (p < 0.001), respectively.
    2 context sentences
    Summary · context
    In this multi-center retrospective observational study, we analyzed subjects with type 2 diabetes newly treated with an oral semaglutide for >6 months at four medical centers located in Sapporo, Japan.
    Summary · context
    Of 543 subjects who met the inclusion criteria, data for 434 subjects (age 55.5 ± 12.6 years; body mass index 29.6 ± 6.0 kg/m2) were analyzed.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes switched from other anti-hyperglycemic agents, including DPP-4 inhibitors, efficacy of oral semaglutide was also confirmed.

    In plain wordsIn adults with type 2 diabetes who switched from other diabetes drugs, oral semaglutide was also reported to work.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedEfficacy in subgroup switched from other agents
    Study

    n = 434

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 mg, 7 mg or 14 mg · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Efficacy was also confirmed in the subgroup switched from other anti-hyperglycemic agents, including dipeptidyl peptidase-4 inhibitors.
    2 context sentences
    Summary · context
    In this multi-center retrospective observational study, we analyzed subjects with type 2 diabetes newly treated with an oral semaglutide for >6 months at four medical centers located in Sapporo, Japan.
    Summary · context
    Of 543 subjects who met the inclusion criteria, data for 434 subjects (age 55.5 ± 12.6 years; body mass index 29.6 ± 6.0 kg/m2) were analyzed.
  5. 05HumanObservational studySafety outcome

    In adults with type 2 diabetes on oral semaglutide, no participant experienced severe hypoglycemic events.

    In plain wordsIn adults with type 2 diabetes on oral semaglutide, no one had severe low blood sugar.

    Peptide
    Semaglutide
    Outcome
    No significant changeSevere hypoglycemic events
    Study

    n = 434

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    3 mg, 7 mg or 14 mg · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    None of the participants experienced severe hypoglycemic events.
    2 context sentences
    Summary · context
    In this multi-center retrospective observational study, we analyzed subjects with type 2 diabetes newly treated with an oral semaglutide for >6 months at four medical centers located in Sapporo, Japan.
    Summary · context
    Of 543 subjects who met the inclusion criteria, data for 434 subjects (age 55.5 ± 12.6 years; body mass index 29.6 ± 6.0 kg/m2) were analyzed.
  6. 06HumanObservational studySafety outcome

    In adults with type 2 diabetes on oral semaglutide, 154 subjects had symptomatic gastrointestinal symptoms.

    In plain wordsIn adults with type 2 diabetes on oral semaglutide, 154 people had stomach and gut symptoms.

    Peptide
    Semaglutide
    Outcome
    Not applicableSymptomatic gastrointestinal symptoms
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    3 mg, 7 mg or 14 mg · oral · 6 monthsAs given in this study (human).

    Measurements

    Subjects with GI symptoms
    154 subjects
    oral semaglutide

    Source sentences

    Summary
    In total, 154 subjects had symptomatic gastrointestinal symptoms
    2 context sentences
    Summary · context
    In this multi-center retrospective observational study, we analyzed subjects with type 2 diabetes newly treated with an oral semaglutide for >6 months at four medical centers located in Sapporo, Japan.
    Summary · context
    Of 543 subjects who met the inclusion criteria, data for 434 subjects (age 55.5 ± 12.6 years; body mass index 29.6 ± 6.0 kg/m2) were analyzed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.